




National Clinical Centre for Research of Emerging Drugs  
(NCCRED)

# Recreational Drug Intoxication Guideline

Dr Andrew Kozman  
Royal Perth Hospital/Fiona Stanley Hospital

Toxicology/NCCRED Fellow

- 
- WISE
  - Clinical Guideline
  - WA Data

# The WISE Study



Western Australian Illicit Substance  
Evaluation



Over 600 patients enrolled,  
commencing Aug 2016



Blood sampling of ED patients  
suspected of being intoxicated with  
**stimulant, hallucinogenic** or  
**cannabinoid** drugs.



Measuring drugs, their  
concentrations and the clinical  
effects



# ED Patients Presenting with Recreational Drug Intoxication Clinical Guideline (RPH)

## Scope

Site	Department, Division or Operational Area	Applicable to
Royal Perth Hospital (RPH) only	Emergency Department (ED), Intensive Care Unit (ICU)	Medical staff



## Fiona Stanley Fremantle Hospitals Group

Guideline

# ED patients presenting with recreational drug intoxication

Reference #: FSFH-ED-GUI-0005

## Scope

Site	Service/Department/Unit	Disciplines
Fiona Stanley Hospital	Emergency Department (ED)	Medical



# Challenges



Site/Hospital  
Approval/Governance



Consent Issues



The Right Patient



Timely Results

# DATA



## Royal Perth Hospital

Inner City

Level 1 trauma centre

200 presentations daily

## Fiona Stanley Hospital

South of Perth 20km

Quaternary Hospital

320 presentations daily

# May 1/5/20-July 30/6/20

RPH	29 CASES 18M: 11F
KETAMINE	1
HEROIN	4
METH/AMPHETAMINE/MDMA	23
LSD	1
GHB	4
ETIZOLAM	2
FLUBROMAZOLAM	2

FSH	42 CASES 27M: 15F
KETAMINE	1
HEROIN	2
METH/AMPHETAMINE/ MDMA	31
LSD	3
GHB	1
ETIZOLAM	1
FLUBROMALPRAZOLAM	2
MDMB-4-en-PINACA SGT-25 AKB48	5





DATA

- Many had amphetamine (derivative) detected
- 90% accurately report what they have taken
- Clinical picture  $\neq$  toxidrome
- Some don't have **ANY** agents in their system
- Rise of novel new agents


# Synthetic Cannabinoids

<b>1</b>	39M	SGT-25	MDMB-4en-PINACA	MDMA	seizure activity
<b>2</b>	30M	AKB 48	MDMA		disordered thought
<b>3</b>	33M	AKB 48			erratic behavior
<b>4</b>	28M	MDMB-4en-PINACA			drowsy
<b>5</b>	27M	AKB 48	SGT-25		seizure activity

# 'Designer' BDZ

<b>1</b>	28M	FLUALPRAZOLAM	-	-	AGITATION
<b>2</b>	31M	ETIZOLAM	FLUALPRAZOLAM	MDMA	SEIZURE
<b>3</b>	27M	ETIZOLAM	DIAZEPAM	DIHYDROCODEINE	LOW GCS/HYPOGLYCAEMIA
<b>4</b>	33F	FLUALPRAZOLAM	GHB	-	DROWSY

# BDZ related deaths by substance, Scotland



# Benefits of Clinical Guideline

- Standard of care
- Identify clusters within 24 hours
  - Hyoscine clusters
  - NBOMBe-5FA
  - MDMA
  - Cathinones
- Objective evidence on drugs causing harm
- Toxicological surveillance
- Evidence-Based Harm Reduction:  
Early warning system

# Acknowledgements

- Jess Soderstrom, David McCutcheon (WISE)
- ChemCentre for sample analysis and reporting
  - Dr Francois Oosthuizen, Dr Bianca Douglas, Dr Colin Priddis, Dr John Coumbaros, Dr Nathan Sumner
- Research Assistants
  - Jennifer Smith, Sophie Damianopoulos
- Medical staff
- Part of this project is supported by funding from the National Centre for Clinical Research on Emerging Drugs (NCCRED), funded by the Australian Government of Health

